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ABSTRACT
An experimental study was performed to evaluate a novel method of controlling protein expression by
repeatedly transfecting cells with in vitro-transcribed RNA. Transcripts encoding six factors, each known
to play an important role in cell-type specification and maintenance, were designed and synthesized.
Aspects of the design were optimized, and the intracellular stability and translation efficiency of the ivT
RNA were quantified. Transcripts were delivered to cells by electroporation, and a method of increasing
the rate at which cells recover from ivT-RNA transfection by combined knockdown of innate-immune-
related genes was developed. Using this technique a high, approximately steady-state level of protein
expression was transduced in MRC-5 human fetal-lung fibroblasts by repeated transfection with capped,
poly(A)+ ivT RNA encoding a protein with an intracellular half-life of approximately three days.
Transfection at 24-hour intervals with ivT RNA encoding a less stable protein resulted in protein
expression that peaked twelve hours after each transfection, and diminished before the next transfection.
In both cases, cells sustained a high rate of proliferation.
In this study, extended transient transfection by repeated delivery of ivT RNA was shown to transduce
expression of defined factors in cultured cells without genetic modification or the extensive screening
required in small-molecule approaches and with significant control over the level of transduced protein.
This technique may become a powerful tool in the development of new directed-differentiation and cell-
type-conversion protocols.
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1. INTRODUCTION
During early mammalian development, stem cells in the blastocyst divide and differentiate, ultimately
forming all the cells of the body. Thomson et al. demonstrated that cells extracted from the inner cell
mass of a developing human embryo can multiply and differentiate in culture1, suggesting the possibility
of using human embryonic stem (hES) cells as an unlimited source of tissue-specific cells for
implantation into patients suffering from a wide range of diseases and injuries. Many debilitating
diseases are characterized by the loss of a single type of tissue-specific cell (Parkinson's, dopaminergic
neuron; multiple sclerosis, oligodendrocyte; type-1 diabetes, insulin-producing 3-cells), and several recent
studies, including a number of controlled clinical trials, have demonstrated that many of the effects of
cell-type-specific diseases can be reversed to varying degrees by implanting cells of the missing cell type
or related cell types into the affected region of the body2-8 . Because many terminally differentiated cell
types do not proliferate readily in culture, multipotent cells must first be expanded and then differentiated
in vitro to produce these tissue-specific cells in the large quantities needed for implantation. For this
reason, the establishment of cultures of human ES cells, cells that proliferate indefinitely and can
differentiate into any cell type, marked a major milestone in the development of new cell-replacement
therapies.
However, developing protocols for the in vitro differentiation of hES cells into pure populations
of tissue-specific cells for both screening and regenerative-medicine applications has proved challenging.
Because it is not yet possible to precisely mimic the changing cellular microenvironments that develop in
vivo, most directed-differentiation protocols are based on the timed application of a small number of
compounds and soluble factors such as retinoic acid, insulin, progesterone, and LIF, in combination with
simple growth substrates such as uniform layers of collagen and laminin 9-14. Although these protocols
can be used to produce large quantities of some types of cells, the resulting cultures generally contain
many cells of undesired cell types, and markers that allow efficient purification of many tissue-specific
cell types by techniques such as fluorescence-activated cell sorting (FACS) remain to be discovered. In
addition, small-molecule differentiation protocols currently exist only for a small number of cell types. A
new technology is needed to direct the differentiation of stem cells into any desired cell type with high
efficiency.
Cell type is determined by the epigenome, the set of chromatin modifications and other factors
that establish the degree to which each of a cell's genes is expressed, and that can be passed to daughter
cells during mitosis"15-1". Cell type is maintained by interconnected networks of factors that stabilize the
cell's gene-expression pattern, while still allowing the cell to respond to environmental cues. The
epigenetic marks that collectively determine cell type are not permanent 19-21, but are written and erased
not only during germ-cell formation and early development, when the chromatin is extensively
remodelled22-26 (for a recent review see Reik, 2007), but also throughout the life of an adult in the many
tissues in which cells must be frequently replaced (olfactory bulb, intestinal glands, hair follicles). The
differentiation that occurs in these stem-cell niches and in embryonic stem cells is controlled by
extracellular cues that initiate cascades of intracellular signalling, which ultimately result in an epigenetic
transition as many genes are silenced and others activated in a process about which much remains
unknown.
One model of epigenetic gene-expression regulation postulates that while the epigenetic state of a
gene is known to influence its expression (for a review of DNA-methylation-mediated gene silencing see
Bird, 2002), the expression of a gene may in turn influence its epigenetic state27 . In this model, epigenetic
marks such as CpG methylation interfere with transcription either directly or through intermediates such
as MeCP1 and MeCP2 28-30 , and as a result genes containing a large number of these marks are silenced.
At the same time, factors that promote transcription of a gene may interfere with the machinery
responsible for copying epigenetic marks to the daughter strand during DNA replication or these factors
may recruit other factors that actively remove the epigenetic marks from a silenced gene, activating it. If
this model is correct, it should be possible to control cell type by inhibiting the factors responsible for
maintaining the epigenetic state of the present cell type while at the same time transiently transducing the
expression of the factors responsible for maintaining the epigenetic state of the target cell type. Rather
than screening libraries of small molecules for compounds that can increase the efficiency of specific
transitions that cells undergo as they differentiate in culture, a method of directly changing the cell's
gene-expression program by transiently transducing known factors would represent an approach to
directed differentiation that could take advantage of the large and growing body of knowledge of the
gene-expression patterns and epigenetic states of different cell types. However, if DNA replication is
required for binding of gene-activating factors, the inhibition and transient transduction of target-cell-type
factors may need to be maintained through one or more cell divisions. While a number of techniques are
available to transiently transfect cells, no technique exists to transduce a high level of expression of a
target gene through multiple rounds of mitosis without genetic modification.
The expression of transcription factors is tightly regulated by the cell, both pre- and post-
transcriptionally, ensuring that cells express proteins appropriate for the tissues that they comprise. At the
same time these factors, as well as the transcripts encoding them, have short intracellular lifetimes,
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enabling the cell to change its program of gene expression rapidly in response to environmental cues. To
stably alter a cell's gene-expression program, many genes must be silenced and others activated. Gene
silencing can be initiated by several mechanisms, many of which involve the association of one or more
factors to the DNA in the region of the gene being silenced31. Because the chromatin surrounding
actively transcribed genes is loose (histones acetylated, histone H3 methylated at lysine 4, and
unmethylated at lysines 9 and 27), transcription factors can easily locate and bind to their targets. To
activate a gene, transcription factors may locate and bind to their targets as in the process of gene
silencing, but because the chromatin surrounding silenced genes is compact (histones deacetylated,
histone H3 methylated at lysines 9 and 27), the transcription-factor binding sites in silenced genes may
generally only be accessible for a short time during mitosis, after DNA replication, but before the
epigenetic marks are copied to the daughter strand. Achieving specific, passive reactivation of a silenced
gene by exogenous means may therefore require that the factors that bind to the regulatory elements in the
gene be present at a sufficient level immediately following DNA replication, and possibly during multiple
sequential cell divisions.
There are several methods of transducing the expression of proteins in non-transformed cells.
Many small molecules have been identified that stimulate the expression of proteins with various degrees
of specificity. However, highly specific small-molecule agonists have not yet been discovered for the
majority of proteins. Alternatively, recombinant proteins can be introduced directly into cultured cells by
lipid-stimulated endocytosis, electroporation or using other transfection techniques. Many proteins
however, are difficult to synthesize in large quantities, with high purity and activity. In addition,
transcription factors delivered directly to cells will be quickly degraded, likely necessitating frequent,
repeated delivery to achieve gene activation. Many of the limitations of both small-molecule and
recombinant-protein-transfection-based protein-transduction techniques can be overcome by using the
cell's own translation machinery to synthesize the required proteins from a DNA or RNA template.
Because the delivery of a single molecule of DNA or RNA can result in the synthesis of many copies of
the protein it encodes, far less material must be delivered to cells when transfecting with DNA or RNA to
achieve an equivalent peak level of intracellular protein than is necessary when transfecting with
recombinant protein. Although exogenous DNA can drive protein expression without being integrated
into the cell's genome, because achieving a stable epigenetic transition likely requires high levels of
transduced protein expression during multiple sequential cell divisions, the risk of ectopic integration in a
repeated-DNA-transfection-based gene-activation technique may be too high to yield cells that are
therapeutically useful. In addition, it is difficult to control the number of copies of DNA delivered to each
cell using available transfection technologies, and as a result it may be difficult to control the level of
transduced protein expression in a repeated transient DNA-transfection protocol.
Delivering in vitro-transcribed (ivT) RNA to cultured cells combines many of the advantages of
both recombinant-protein transfection and DNA transfection, while avoiding many of the problems
associated with each of these techniques. Like DNA transfection, RNA transfection relies on the cell's
translation machinery to synthesize a large quantity of protein from a small amount of exogenous
material, minimizing the cellular stress caused by frequent transfections, while like protein transfection,
RNA transfection carries no risk of ectopic integration.
We demonstrate a method of extended transient transfection by repeated delivery of ivT RNA.
By repeatedly transfecting proliferating cells with ivT RNA encoding factors known to play key roles in
cell-type specification and maintenance, we hypothesize that the epigenetic state of the transfected cells
can be controlled, and that the cell type of the transfected cells can be changed to any desired cell type.
ivT-RNA transfection is used widely to study a variety of cellular processes where the transient
overexpression of one or more genes is desired32-34, and high-efficiency, high-viability transfection of hES
cells with ivT RNA has recently been demonstrated"3 . Although techniques for the in vitro synthesis of
large quantities of capped, polyadenylated RNA have been available for some time36-3 9, as have a variety
of delivery techniques including electroporation and lipid-mediated transfection40 45, the comparative ease
of DNA-vector synthesis and transfection, as well as the ability to stably transfect cells with DNA has
limited the use of RNA in experiments requiring transduced protein expression. However, because
chromatin remodelling is a transient process, we hypothesize that controlling a cell's epigenetic state will
require only transient overexpression of key factors. For this reason, and because genetically modifying
cells by DNA transfection could make them unsafe for regenerative-medicine applications, extended
transient transfection by repeated delivery of ivT RNA may become a powerful tool in the development
of new directed-differentiation and cell-type conversion protocols.
The following sections describe an experimental study undertaken to assess the feasibility of
controlling gene expression by extended transient transfection with ivT RNA. First, the design and
synthesis of stable, efficiently translated transcripts encoding factors known to play key roles in
determining cell type are detailed. Next, efficient methods of delivering these transcripts to cultured cells
are explored, and the intracellular stability and translation efficiency of the transcripts are quantified.
Finally, a method of extended transient transfection by repeated delivery of ivT RNA is presented, and the
possibility of using this method to control cell type is discussed.
2. TRANSCRIPT DESIGN
Although the intracellular lifetime of most mRNA molecules is only a few hours, the degradation
rate of an mRNA molecule is strongly affected by sequence elements present in its untranslated regions
(UTRs). Replacing the UTRs of a synthetic transcript with those of a more stable mRNA molecule has
been shown to increase the intracellular stability of the synthetic transcript, thus increasing the amount of
protein that can be translated42 . Also, the sequence surrounding the start codon of an mRNA molecule
(known as the "Kozak sequence") has been shown to play a crucial role in determining the efficiency with
which the mRNA is translated into protein46. Both stabilizing a synthetic transcript by replacing its UTRs
with those of a more stable mRNA molecule and increasing the efficiency with which the transcript is
translated by selecting a Kozak sequence with strong consensus minimize the amount of ivT RNA that
must be delivered to achieve a given level of intracellular protein, thus minimizing the cellular stress
caused by frequent transfections.
In this study six transcripts were designed, each encoding a factor known to play a key role in
cell-type specification and maintenance. Five transcription factors and one mRNA-binding protein were
selected based on their known gene targets, their participation in differentiation and the maintenance of
gene-expression programs, and the length of their coding sequences. Sections 2.1 through 2.3 describe
the design of a generic template for the in vitro transcription of a stable, efficiently translated transcript
encoding an arbitrary protein.
2.1. Using [-globin untranslated regions to increase the intracellular stability of ivT RNA
The stability of an mRNA molecule is determined primarily by the sequences of its 5'- and 3'-UTRs,
which regulate degradation by associating with specific factors47 -49. Replacing either the 5'- or 3'-UTR of
an unstable RNA molecule with the corresponding UTR of a more stable RNA molecule has been shown
to significantly increase its stability, while replacing both UTRs results in a further increase in stability42.
For targeted gene activation by repeated transfection with ivT RNA, highly stable RNA is desired to
minimize the transfection frequency needed to maintain the required level of transduced protein.
The 0-globin gene (HBB) encodes one of the most stable mRNA molecules known 49. In addition,
the HBB UTRs are short (5'-UTR = 50nt, 3'-UTR = 132nt), and as a result they contribute only a small
amount of mass to a protein-encoding transcript of average length, giving the complete transcript a high
copy-to-mass ratio. For these reasons, HBB UTRs were selected to stabilize the transcripts synthesized in
this study, and an in vitro-transcription template including both the HBB 5'- and 3'-UTRs was designed to
maximize the intracellular stability of the ivT RNA.
2.2. Designing a Kozak sequence for efficient translation of ivT RNA
The efficiency with which an mRNA molecule is translated into protein is determined primarily by three
factors: the presence of a 7-methylguanosine (m7G) cap at the 5' end, the presence of a poly(A) tail at the
3' end, and the sequence surrounding the start codon, known as the "Kozak sequence". The presence of
certain nucleotides as specific positions relative to the start codon of an mRNA molecule can have a
dramatic effect on the efficiency with which it is translated 46 . The consensus sequence yielding
maximum translation efficiency is: RCC(AUG)G, with the start codon in parentheses, and the "R" at
position -3 representing a purine (A or G). Of the non-coding nucleotides, the bases at positions -3 and -1
are the most critical for a strong consensus and efficient translation. The dependence of translation
efficiency on the sequence surrounding the start codon has been explained by a model of translation in
which certain portions of the mRNA sequence that are complementary to the ribosome can cause the
translation complex to pause near the start codon, increasing the probability of translation initiation.
To maximize the efficiency with which ivT RNA can be translated into protein once delivered to
cells, a design including all three elements (m7G cap, poly(A) tail, and a Kozak sequence with strong
consensus) was selected. While the m7G cap and poly(A) tail can be added to RNA after in vitro
transcription using recombinant enzymes, the Kozak sequence is copied from the template during
transcription, and as a result, must be defined during template assembly.
2.3. Requirements for ivT-template assembly and in vitro transcription
Recombinant T7 bacteriophage RNA polymerase is widely used for in vitro transcription from a DNA
template containing the minimal T7 promoter sequence, TAATACGACTCACTATAGGG, with the last
three bases (GGG) encoding the first three nucleotides of the transcript (also GGG). Several commercial
in vitro-transcription kits are available that use this enzyme together with buffers and additives designed
to produce high yields of full-length transcripts. Linearized plasmids, PCR products, and single-stranded
oligonucleotides can be used as T7 RNA-polymerase templates, although the T7 promoter must be
double-stranded. For this study, to simplify the template synthesis procedure while minimizing sequence
errors, the in vitro-transcription template was designed as a blunt-ended PCR product to be produced by a
high-fidelity DNA polymerase from reverse-transcribed poly(A)+ mRNA. Choosing a PCR product
facilitates the production of large quantities of template without the need for bacterial cloning, and
eliminates the linearization step required when using a plasmid template. Amplifying reverse-transcribed
poly(A)+ mRNA ensures that the sequences of the ivT-template components will match those of mature
endogenous transcripts.
To produce dsDNA templates for T7 in vitro-transcription reactions, a sticky-end ligation was
designed to combine the HBB UTRs with an arbitrary CDS using the two restriction endonucleases, Nhel
(recognition site: G/CTAG\C) and Agel (recognition site: A/CCGG\T), which are active in the same
buffer, allowing a combined digestion. Primers containing the T7 promoter, a Kozak sequence with
strong consensus, and the restriction enzyme recognition sites were designed to facilitate the
incorporation of these elements into the ivT-template components during PCR. Five adenosine residues
were included on the 5' ends of the HBB 5'-UTR reverse primer and the HBB 3'-UTR forward primer to
facilitate digestion. The HBB UTR primer sequences are shown below with the T7 promoter and
restriction-enzyme recognition sites underlined. A diagram of the assembled HBB-UTR-stabilized
Kozak+ (HUSK) in vitro-transcription template is shown in Figure 2.1.
HBB 5 '-UTR Forward Primer: TAATACGACTCACTATAGGGACATTTGCTTCTGACACAACTGTG
HBB 5'-UTR Reverse Primer: AAAAAGCTAGCTGTTTGAGGTTGCTAGTGAACACAGTTGTG
Product Length: 75bp
HBB 3'-UTR Forward Primer: AAAAAACCGGTGCTCGCTTTCTTGCTGTC
HBB 3 '-UTR Reverse Primer: GCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATG
Product Length: 143bp
T7 Promoter 4 vNhel CDS Y HBB 3'-UTR
TAATACGACTCACTATAGGGACATTT * * * CAAACAGCTAGCCACCATG * * * ACCGGTGCTCGC * * * CATTGC
HBB 5'-UTR A Kozak AgelA
Figure 2.1. HBB-UTR-stabilized Kozak+ (HUSK) in vitro-transcription template. A generic ivT
template was designed to maximize transcript stability and translation efficiency. The template is a blunt-
ended PCR product synthesized using a high-fidelity polymerase from reverse-transcribed poly(A)+
mRNA. The long arrow indicates the first base transcribed by T7 RNA polymerase. The short arrows
indicate restriction-enzyme cleavage sites.
3. TRANSCRIPT SYNTHESIS
Capped, poly(A)+ transcripts were synthesized in T7 in vitro-transcription reactions from six linear
dsDNA templates, each containing a T7 RNA polymerase promoter, HBB 5'- and 3'-UTRs, a Kozak
sequence with strong consensus, and a coding sequence amplified from reverse-transcribed poly(A)+
mRNA. A high-fidelity polymerase was used in all stages of the dsDNA template synthesis to minimize
sequence errors. Denaturing formaldehyde-agarose gel electrophoresis was performed to confirm that the
transcripts had the expected size before polyadenylation, that they were undegraded, and that the
polyadenylation reaction added a poly(A) tail of sufficient length to promote efficient translation.
Although full-length transcripts were produced from each template, completed reactions also contained
large amounts of low-molecular-weight products, identified as a combination of prematurely terminated
and degraded transcripts. Reducing the temperature of the in vitro-transcription reaction dramatically
increased the fraction of full-length transcripts produced.
3.1. ivT-template synthesis
H9 human embryonic stem cells were obtained from the National Stem Cell Bank at passage 24, and were
cultured on irradiated mouse embryonic fibroblasts (MEFs) derived from E13 CF-1 mice (Charles River
Laboratories) as described1 (see Methods). The hES cells grew as large colonies of compact cells with
little cytoplasm (Fig. 3.1 A). Cells grown on MEFs were stained with antibodies against the pluripotency
markers Oct4 and Nanog. hES-cell colonies contained many brightly stained cells, while the MEFs were
not stained (Fig. 3.1 B and C). After several passages, some cells were plated on dishes coated with BME
basement membrane matrix (Trevigen), and were cultured in media conditioned for 24 hours on irradiated
MEFs and supplemented with 4ng/mL bFGF (Invitrogen) and 10pM of the ROCK inhibitor Y-27632
(Cayman Chemical)5o. Cells grown in conditioned media with Y-27632 exhibited very low levels of the
spontaneous differentiation observed in cells grown on MEFs or in conditioned media without Y-27632.
A. B.
Oct4 Nanog Hoechst
Hoffman Modulation Contrast (HMC) Merge
C.
Figure 3.1. H9 human embryonic stem cells. Colonies of H9 hES cells are shown with fibroblast
feeders in bright field (A) and stained for pluripotency markers (B: red, Oct4; green, Nanog; blue,
Hoechst). Poly(A)+ mRNA was reverse transcribed from these cells to generate ivT-template sequences.
C: A small colony of H9 hES cells grown on a fibroblast feeder layer is shown stained for the
pluripotency markers Oct4 (red) and Nanog (green). These proteins are localized to the nuclei of G -
phase cells as expected.
Total RNA was extracted from H9 hES cells cultured in conditioned media on BME-coated plates
using RNeasy midi kits (Qiagen) with an on-column DNAseI digestion. Poly(A)+ mRNA was enriched
using poly(dT) latex beads (Oligotex, Qiagen), quantitated (Quant-iT, Invitrogen) and stored at 4C in
5mM Tris-HC1, pH 7.5. Poly(A)+ mRNA was reverse transcribed in separate reactions using an RNase
H- reverse transcriptase (MonsterScript, Epicentre) and primers designed to anneal to the 3' ends of the
HBB 3'-UTR and the CDSs of the six genes selected for this study (Table B.1).
The HBB 3'-UTRs and the six CDSs were then amplified using a high-fidelity polymerase
(Phusion Hot-Start, NEB) to minimize sequence errors (Tables B.2-B.4). The HBB 5'-UTR primers span
the entire PCR product, eliminating the need for a cDNA template in the HBB 5'-UTR amplification
reaction. The primers were designed to attach the T7 promoter sequence to the 5' end of the HBB 5'-UTR
and restriction-enzyme recognition sequences to the 3' end of the HBB 5'-UTR, the 5' end of the HBB 3'-
UTR, and both ends of the CDSs. The reaction products were separated on a 1.5% (CDSs) or a 3% (HBB
UTRs) agarose gel, the appropriate bands were excised, and the DNA extracted (Gel Extraction Kit,
Qiagen) (Fig. 3.2).
A. B. C.
Figure 3.2. In vitro-transcription template components. The HBB 5'-UTR (A), and 3'-UTR (B) PCR
products and the six CDS PCR products (C) are shown after amplification from cDNA generated by
reverse transcribing H9 poly(A)+ mRNA. Ladders: TriDye 2-Log DNA Ladder (NEB).
The PCR products were digested using NheI and Age I restriction enzymes (Table B.5), purified
(Gel Extraction Kit, Qiagen), and ligated to form the complete ivT templates (Table B.6). The ligation
reactions were separated on a 1.5% agarose gel, the appropriate bands were excised, and the DNA
extracted (Fig. 3.3 A). Extracted DNA was amplified using the HBB 5'-UTR Forward Primer and the
HBB 3'-UTR Reverse Primer to obtain microgram-quantities of the assembled ivT templates (Table B.7,
Fig. 3.3 B).
A. B.
Figure 3.3. ivT-template ligation products. The ivT-template ligation reactions were separated on a
1.5% agarose gel (A), the appropriate bands were excised, the DNA extracted, and the assembled ivT
templates were amplified. B: Amplified ligation products were separated on a second 1.5% agarose gel.
Ladders: TriDye 2-Log DNA Ladder (NEB).
A large-scale amplification was then performed to produce the quantity of each template required
for in vitro transcription (Table B.8). Completed amplification reactions were subjected to two sequential
gel purifications to remove nonspecific products (Figs. 3.4 and 3.5).
B.
Figure 3.4. ivT-template large-scale amplification. A second round of amplification was conducted to
produce the large quantity of template required for in vitro transcription. Two sequential gel extractions
were carried out to purify the products (amplification products before (A) and after (B) the first gel
extraction are shown). Ladders: TriDye 2-Log DNA Ladder (NEB).
Lane 1 2 3 4 5 '6 7 8
Figure 3.5. In vitro-transcription templates. The assembled templates each travel as a single, sharp
band of the expected size on a 1.5% agarose gel. Lanes 1,8, TriDye 2-Log DNA Ladder (NEB); Lanes 2-
7, HUSK ivT templates A-F.
3.2. In vitro transcription
Although tens of micrograms of a 1kb transcript can be synthesized from one microgram of template
DNA in a 20pL ivT reaction in one hour at 37C, template sequence elements that resemble the T7
termination sequence and template secondary structure can result in premature termination, yielding
incomplete transcripts. Several reports indicate that modifying the ivT reaction by adding single-strand
binding protein (SSB)51 or by reducing the reaction temperature 52 can reduce premature termination and
increase the fraction of full-length transcripts produced. Although there is a significant reduction in T7
RNA-polymerase processivity at temperatures lower than 37C (Fig. 3.6, A, B), the specificity of the
reaction is increased (Fig. 3.6 C), and a yield equivalent to that obtained at 37C can be obtained at 10C by
increasing the duration of the reaction from 1 hour to 20 hours.
Ladder ivT Reaction Temperature/C
37 30 25 20 10 4
...... +-- Full-length transcript
SIncomplete transcripts
A.
120 3.5SFull-length transcript
100 Incomplete transcripts 
- 3 *
"; 80C 
o. 2.5
0 1
0 10 20 30 40 0 10 20 30 40
B. ivT Reaction Temperature/C C. ivT Reaction Temperature/C
Figure 3.6. ivT-reaction specificity. A large in vitro-transcription reaction (mScript, Epicentre) was
assembled, aliquoted, and incubated at various temperatures for 1 hour. A: Aliquots of each reaction
were resolved on a denaturing formaldehyde-agarose gel (see Methods), and stained with SYBR Gold
(Invitrogen). B: The intensities of the bands corresponding to the full-length and incomplete transcripts
were averaged across each lane, and the peak intensities plotted against reaction temperature. Data points
are connected for clarity. C: The ratio of the peak intensities is plotted against reaction temperature,
showing a significant increase in reaction specificity as the temperature of the reaction is decreased from
37C to 10C. An exponential regression excluding the 4C data point is also shown (black line).
Each HUSK ivT template was added to a T7 ivT reaction (mScript mRNA Production System,
Epicentre, Table B.9), and the resulting RNA was purified (RNeasy Mini Kit, Qiagen), quantitated,
capped, and polyadenylated (mScript, Epicentre, Tables B.10 and B. 11). The capped, poly(A)+ ivT RNA
was purified, quantitated, and stored at 4C in RNase-free water with an RNase inhibitor (SUPERaseIn,
Ambion). 11tg of each transcript both before and after poly(A) tailing was analyzed by denaturing
formaldehyde-agarose gel electrophoresis (see Methods) to confirm that each transcript had the expected
size before poly(A) tailing, to assess the level of degradation, and to measure the length of the poly(A) tail
(Fig. 3.7 A). The duration of the polyadenylation reaction was adjusted to yield a poly(A) tail of
approximately 150 nucleotides.
In addition to the six HUSK transcripts, full-length Transcript A was synthesized using a template
containing the complete sequence of the endogenous mRNA (endogenous UTRs and an unmodified
Kozak sequence, Fig. 3.7 B). In all reactions low-molecular-weight products appeared after
polyadenylation (dim features below dark bands). The polyadenylation reaction contains an RNase
inhibitor, suggesting that the polyadenosine polymerase itself may possess a low level of RNase activity.
Transcript
A B C D E F
3kb --
2.5kb--+
2kb -
1.5kb --
lkb-.|
0.5kb-+.
S
p
HUSK Full Length
3kb --
2.5kb--+
1kb --+
0.5kb--+ *S
Poly(A) - + - + - + - + - + - + B. Poly(A)
Figure 3.7. In vitro-transcribed RNA. A: HUSK Transcripts A-F, each before and after poly(A) tailing,
were analyzed by denaturing formaldehyde-agarose gel electrophoresis (see Methods). The dim, low-
molecular weight features below each band represent a combination of prematurely terminated transcripts
and degradation products. B: HUSK and full-length Transcript A.
+ - +
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4. DELIVERY OF IN VITRO-TRANSCRIBED RNA TO CELLS
MRC-5 human fetal-lung fibroblasts were chosen as the model for this study because they are easily
cultured, they undergo several population doublings before the onset of senescence, and because as
primary cells, they represent a more appropriate model for the development of cell-based therapies than
would an immortalized cell line, the use of which in patients could present a safety risk due to the
possibility of tumorigenesis. In addition, MRC-5 fibroblasts do not endogenously express the proteins
encoded by Transcripts A-F, facilitating the analysis of protein translation from ivT-RNA. Sections 4.1-
4.3 summarize available methods for delivering RNA to cells with high efficiency and high viability, and
describe experiments conducted to assess both the intracellular stability of ivT RNA and the efficiency
with which it is translated into protein.
4.1. Summary of delivery methods
Two nucleic-acid-delivery techniques are commonly used to transiently transfect cells: lipid-mediated
transfection, and electroporation. Lipid-mediated transfection stimulates active uptake of nucleic acids by
endocytosis, while electroporation delivers nucleic acids by transiently opening holes in the cell
membrane while the cell is in a solution in which the nucleic acid is present at high concentration. This
difference generally makes lipid-mediated transfection more suitable for delivering nucleic acids to cells
under close-to-normal growth conditions (normal culture media, although often without serum, normal
plating density, and attached to a culture dish if the cells are grown in adherent culture.)
To determine whether ivT RNA produced as described in Section 3 is readily translated into
protein by primary cells, Transcripts A, B, and F were delivered to cultures ofMRC-5 fibroblasts using a
lipid-mediated transfection reagent (TransIT, Mirus Bio, see Methods), and the cells were stained 24
hours later using antibodies against the proteins encoded by each transcript (Fig. 4.1). As can be seen in
the figure, many of the cells in cultures transfected with ivT RNA stained brightly, and staining was
correctly localized (A,B, nucleus; F, cytoplasm), while mock-transfected cells exhibited only a low level
of background fluorescence. Cells that normally express the proteins encoded by Transcripts A-F (H9
hES cells) exhibited a similar staining pattern and intensity (not shown), suggesting that the level of
protein in MRC-5 fibroblasts 24 hours after transfection with ivT RNA under these conditions is
comparable to the level endogenously expressed by H9 cells. A western-blot analysis yielded similar
results (not shown.)
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Figure 4.1. Transfection of MRC-5 fibroblasts with ivT RNA. Transcripts A, B, and F were delivered
to MRC-5 fibroblasts by lipid-mediated transfection (TransIT, Mirus Bio, see Methods). Cells were
stained using antibodies against the proteins encoded by each transcript 24 hours after transfection.
Although lipid-mediated transfection is a simple method for delivering RNA to cells, lipids are
known to be inefficient when used to transfect cultures of primary cells, which generally exhibit low
levels of endocytosis. In addition, the potential cytotoxicity of the lipid and ancillary nucleic-acid-
condensing compounds often used to increase lipid-mediated-transfection efficiency must be taken into
account in any lipid-transfection experiment. While cells transfected using lipids may recover quickly,
any cytotoxicity associated with lipid-mediated transfection reagents may be compounded in cells that are
repeatedly transfected. To attain the level of protein shown in Figure 4.1, transfection with a high
concentration of lipid-RNA complexes was required, and increasing the amount of RNA delivered to the
cells beyond this level resulted in decreased viability.
As a result of the low transfection efficiency and low viability associated with lipid-mediated
RNA transfection of primary cells, electroporation was explored as a method for delivering large
quantities of ivT RNA to MRC-5 fibroblasts with minimal cytotoxicity. Although adherent cells can be
electroporated, because the cell membrane is permeabilized only transiently during electroporation, the
concentration of the nucleic acid in the electroporation buffer must be high (a value of 100g/mL RNA is
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often used) to achieve a high intracellular concentration. For this reason, electroporation is generally
most suitable for transfecting cells in suspension, and allows the transfection of a large number of cells
using a small amount of RNA.
Electroporation parameters were optimized by transfecting MRC-5 fibroblasts with ivT RNA, and
measuring transfection efficiency by quantitative RT-PCR using primers designed to specifically detect
the exogenous transcripts. Discharging a 150uF capacitor charged to 145V into 2.5x10 6 cells suspended
in 50#tL of Opti-MEM (Invitrogen) in a standard electroporation cuvette with a 2mm gap was sufficient to
repeatably deliver in excess of 10,000 copies of ivT RNA per cell, as determined using the standard curve
method, while maintaining high viability (70-90% of cells adherent 2 hours after plating). Further
experiments revealed that the voltage required to efficiently transfect cells with ivT RNA depends on the
cell density during electroporation. While 145V was necessary to transfect cells at a density of 2.5x106
cells/50pL, as little as 110V was used to transfect cells at a density of 1x10 6 cells/50iL with the same
efficiency (same number of copies per cell).
4.2. Intracellular stability of ivT RNA
To determine the intracellular lifetime of ivT RNA and to compare the relative intracellular stability of
HUSK and full-length transcripts, MRC-5 fibroblasts were transfected with 2[pg of full-length Transcript
A or HUSK Transcript A or F, and the intracellular concentration of each transcript was measured 2, 4, 12,
and 24 hours after transfection (Fig. 4.2). RNase A was added to the culture medium at a concentration of
100/g/mL to eliminate extracellular ivT RNA. The concentration of each of the HUSK transcripts
reached 25% of its level at 2 hours approximately 17-18 hours after transfection, while the concentration
of the full-length transcript reached 25% of its level at 2 hours approximately 10 hours after transfection,
indicating that the intracellular stability of the HUSK transcript is significantly higher than that of the full-
length transcript, and that the stabilities of the two HUSK transcripts are comparable.
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Figure 4.2. Intracellular stability of ivT RNA. MRC-5 fibroblasts were transfected with 2pig of HUSK
Transcript A or F or full-length Transcript A, and the intracellular concentration of each transcript was
measured 2, 4, 12, and 24 hours after transfection. GAPDH was used as a loading control. Exponential
regressions are shown for the HUSK-transcripts (solid lines) and the full-length-transcript (dashed line).
Error bars show the pooled standard deviation of replicate samples.
4.3. Protein translation from ivT RNA
To compare the efficiency with which HUSK ivT RNA is translated relative to the corresponding
full-length transcript without HBB UTRs or a modified Kozak sequence, MRC-5 fibroblasts were
transfected with either HUSK or full-length Transcript A, and protein was extracted after 12 hours and
analyzed by western blot (Fig. 4.3, see Methods). As can be seen in the figure, 12 hours after
electroporation, the cells transfected with HUSK Transcript A contained approximately twice as much of
the encoded protein as the cells transfected with the full-length transcript, indicating that transfecting cells
with ivT RNA based on the HUSK design results in the generation of significantly more protein per
transcript than transfection with the full-length transcript.
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Figure 4.3. Efficiency of translation from HUSK and full-length ivT RNA. MRC-5 fibroblasts were
transfected with 2,ig of HUSK or full-length Transcript A and protein was extracted after 12 hours. The
numbers below each lane represent the amount of protein encoded by Transcript A relative to the level in
H9 cells. ACTB was used as a loading control.
To understand how the concentration of encoded protein changes over time in cells transfected
with ivT RNA as the RNA and protein are degraded, cells were transfected with HUSK Transcript A, B
or F, and protein was extracted every 6 hours for 48 hours and analyzed by western blot (Fig. 4.4, see
Methods). As can be seen in the figure, the levels of the proteins encoded by Transcripts A and B
increase rapidly, peak approximately 12 hours after transfection, then decrease rapidly, and are barely
detectable after 30 hours. However, the level of the protein encoded by Transcript F increases rapidly,
reaching its maximum value approximately 18-24 hours after transfection, and then remains fairly
constant through the 48-hour time point, suggesting that the protein encoded by Transcript F is
significantly more stable than those encoded by Transcripts A and B. Further analysis revealed that the
protein encoded by Transcript F has an intracellular half-life of approximately 3 days when transfected
under these conditions (not shown.)
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Figure 4.4. Time-evolution of expression of translated protein following ivT-RNA transfection.
Transcripts A, B, or F were delivered to MRC-5 fibroblasts by electroporation, and whole-cell lysates
were prepared at the indicated times. A western blot was performed to measure the time-evolution of
expression of the encoded proteins (see Methods). A sample of cells that normally express the encoded
proteins (H9) was used for comparison. ACTB was used as a loading control.
In order to maintain the high level of expression achieved during the first 18-24 hours following
transfection with HUSK Transcripts A and B through multiple rounds of cell division, additional
transfections, performed at intervals of no longer than 24 hours, are likely required. The following
section describes the development of a method of increasing the rate at which cells recover from ivT-
RNA transfection, enabling frequent repeated transfection of proliferating cells.
5. EXTENDED TRANSIENT TRANSFECTION
5.1. ivT RNA elicits an innate-immune response in MRC-5 human fetal-lung fibroblasts
MRC-5 fibroblasts were transfected with capped, poly(A)-tailed HUSK ivT RNA, and observed for
several days. While mock-transfected cells recovered quickly, achieving a normal population-doubling
time within 24 hours, the cells transfected with ivT RNA failed to proliferate for approximately 36 hours,
then recovered, achieving a normal doubling time 48 hours after transfection. Because the duration of the
cytostatic effect of ivT-RNA transfection corresponds roughly to the measured intracellular lifetime of the
ivT RNA (Fig. 4.2), and because transfection with transcripts encoding proteins with both short (less than
24h) and long (greater than 48h) lifetimes yielded similar results (Fig. 5.3), a reaction to the ivT RNA
itself, and not the encoded protein, was suspected. Interestingly, siRNA-mediated knockdown of p53
increased the rate of recovery of the cells transfected with ivT RNA, suggesting that p53-mediated cell-
cycle arrest and/or apoptosis may contribute to the observed cytostatic effect of ivT-RNA transfection
(Fig. 5.1).
Several innate-immune pathways have been discovered that are activated by exogenous RNA.
Toll-like receptor 3 (TLR3) 53' 54, toll-like receptor 7 (TLR7) 55, and retinoic-acid receptor responder
(tazarotene induced) 3 (RARRES3) 56-58 are the three pattern-recognition receptors (PRRs) for which RNA
is a known pathogen-associated molecular pattern (PAMP) in humans. Once exogenous RNA is detected
by these receptors, they initiate cascades of intracellular signaling that result in the upregulation of
interferon-0 (IFNB 1), a cytokine that is secreted into the culture media, from which it is bound by
membrane-associated receptors. These receptors initiate signaling cascades that lead to a full innate-
immune response characterized by growth inhibition, eukaryotic translation initiation factor 2-alpha
kinase 2 (EIF2AK2)-mediated translation inhibition 5 60, upregulation of PRRs, which hypersensitizes the
cells to PAMPs, and upregulation of type I interferons, which are secreted by the cells, amplifying the
immune response. If the cell is unable to clear the infection, the innate-immune response can lead to
apoptosis.
Quantitative RT-PCR revealed a >5,000-fold overexpression of interferon-0 in cells transfected
with ivT RNA 24 hours after transfection relative to mock-transfected cells. In addition, >50-fold
overexpression of TLR3 and RARRES3, >10-fold overexpression of signal transducer and activator of
transcription 1 (STAT 1), and >5-fold overexpression of signal transducer and activator of transcription 2
(STAT2) and EIF2AK2 were found, indicating a type I-interferon response and hypersensitization of the
cells to exogenous RNA (Fig. 5.2).
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Figure 5.1. The cytostatic effect of ivT-RNA transfection. MRC-5 fibroblasts were electroporated in
Opti-MEM (Invitrogen) containing 200nM TP53 siRNA as indicated and plated in 10cm dishes at a
density of 2.5x10 6 cells per dish on day 0. Two days later, the cells were suspended by trypsinization and
electroporated with 3.5#g ivT RNA or 3.5#g ivT RNA and 200nM TP53 siRNA as indicated. Only the
cells that received siRNA on day 0 received additional siRNA on day 2. The confluency of each dish was
monitored for several days. The cells that were not transfected with ivT RNA (squares, diamonds)
recovered quickly after the second electroporation, and those dishes approached confluency at day 3.5,
while the cells that were transfected with ivT RNA (triangles) exhibited delayed growth, and only
approached confluency at day 6. Interestingly, the cells transfected with TP53 siRNA (crosses) showed
an increased rate of recovery after ivT-RNA delivery, approaching confluency at day 5, suggesting that
the cytostatic effect of ivT-RNA transfection may be due in part to activation of a p53-dependent pathway.
Data points are connected for clarity.
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quantitative RT-PCR 24 hours after transfection. TFNB 1 was 7500-fold overexpressed in cells transfected
with ivT RNA compared to mock-transfected cells. In addition, the two PRRs, TLR3 and RARRES3,
were >50-fold overexpressed, and the signaling molecules STAT 1, STAT2, and the protein kinase
EIF2AK2 were >5-fold overexpressed in transfected cells, suggesting significant activation of innate-
immune pathways. GAPDH was used as a loading control. Error bars show the pooled standard
deviation of replicate samples.
To determine whether the innate-immune response elicited by ivT-RNA transfection was affected
by the length or sequence of the RNA, cells were transfected with HUSK Transcript A, B, or F, or full-
length Transcript A, and JFNB 1 expression was measured after 24 hours (Fig. 5.3). Interestingly, HUSK
Transcript F and full-length Transcript A elicited 10-20-fold less IFNB 1 overexpression compared to
mock-transfected cells than HUSK Transcript A or B. While the observation that transfection with full-
length Transcript A results in less IFNB 1 overexpression than transfection with HUSK Transcript A is
likely explained by the shorter intracellular lifetime of the full-length transcript, the observation that
transfection with HUSK Transcript F results in 20-fold less IFNB 1 overexpression than transfection with
either HUSK Transcript A or B also suggests that the innate immune response is not transduced primarily
by the HBB UTRs, which are present in all three transcripts.
The fact that toll-like receptor 7 (TLR7), the PRR for which single-stranded RNA is a known
PAMP is not expressed in MRC-5 fibroblasts (RT-PCR data not shown), while TLR3 and RARRES3, the
two PRRs for which double-stranded RNA is a known PAMP are expressed, combined with previous
observations that ivT RNA and mRNA can elicit a TLR3-dependent innate-immune response 54, 61
suggests that single-stranded RNA can activate TLR3. Long ssRNA molecules can possess significant
secondary structure, which may bind to TLR3 and/or other dsRNA-specific PRRs, activating them. In
this case, longer ssRNA molecules with more secondary structure might elicit a stronger innate-immune
response than shorter ssRNA molecules with less secondary structure. This hypothesis could explain the
lower level of IFNB 1 overexpression transduced by HUSK Transcript F compared to HUSK Transcript A,
as HUSK Transcript A is approximately twice as long as HUSK Transcript F (Fig. 3.7). Additional
experiments using RNA sequences of various lengths are needed to rule out the possibility that the
observed difference in IFNB 1 overexpression is due to specific sequence elements present in the three
HUSK transcripts tested.
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Figure 5.3. Comparing the innate-immune response elicited by different transcripts. A: MRC-5
fibroblasts were transfected with 21lg of HUSK Transcript A, B, or F, or full-length Transcript A, and the
level of IFNB 1 expression was measured after 24 hours. GAPDH was used as a loading control. Error
bars show the pooled standard deviation of replicate samples. B: The transfected cells were monitored for
several days and estimates of confluency were made at the indicated times. Data points are connected for
clarity.
5.2. Disrupting innate-immune-response amplification by interferon-p (IFNB1) knockdown
Because its activation is characterized by growth inhibition, the innate immune system represents a
significant obstacle to any strategy of extended transient transfection based on frequent, repeated delivery
of exogenous RNA, a known PAMP. To disrupt the innate-immune response, siRNA targeting IFNB 1
was delivered to MRC-5 fibroblasts by electroporation, with or without ivT RNA. While the cells that
received no siRNA exhibited a 10,000-fold overexpression of IFNB 1 24 hours after ivT-RNA transfection
compared to mock-transfected cells, the cells that received both siRNA and ivT RNA exhibited only 50-
100-fold overexpression of IFNB 1 compared to mock-transfected cells, corresponding to a knockdown
efficiency of 99-99.5% (Fig. 5.4 B).
To give the RNAi machinery more time to locate and bind the siRNA before ivT-RNA
transfection, cells were electroporated with siRNA, allowed to grow for 48 hours, and then electroporated
with both siRNA and ivT RNA. In this experiment, the cells that received no siRNA showed a 7500-fold
overexpression of IFNB 1 relative to mock-transfected cells, while the cells that received siRNA showed a
15-fold overexpression of IFNB 1 relative to mock-transfected cells, corresponding to a knockdown
efficiency of 99.8% (Fig. 5.4 A). The differences in IFNB 1 overexpression in cells that received only ivT
RNA measured in these two experiments and in those described elsewhere in this text were likely due to
small variations in the extremely low level of IFNB 1 endogenously expressed by MRC-5 cells. For this
reason, levels of overexpression should only be compared within and not between experiments, as each
experiment has an independent mock-transfection control to which all expression data in that experiment
are normalized.
Because knockdown efficiencies observed with electroporation in MRC-5 fibroblasts using
siRNAs from the same vendor targeting other genes are typically between 80% and 90% (Figs. 5.6, 5.7),
the high efficiency of IFNB 1 knockdown observed in these experiments suggests that enough IFNB 1
mRNA was destroyed by the RNAi machinery to disrupt the interferon-p-mediated amplification of the
innate-immune response elicited by ivT-RNA transfection. This hypothesis is supported by the
observation that several other genes involved in the innate immune response, although still overexpressed
relative to mock-transfected cells, are significantly less overexpressed in cells that received siRNA
targeting IFNB 1 than in cells that received no siRNA (Fig. 5.4 A). In particular, the PRRs TLR3 and
RARRES3, which are 50-60-fold overexpressed in cells that received only ivT RNA are 20-30-fold
overexpressed in cells that received both ivT RNA and IFNB 1 siRNA. In addition, STAT 1, STAT2, and
EIF2AK2 all showed a similar reduction in the level of overexpression relative to mock-transfected cells
when cells were co-transfected with ivT RNA and IFNB 1 siRNA.
Although siRNA-mediated IFNB 1 knockdown reduces the overexpression of several genes
involved in the innate-immune response elicited by ivT-RNA transfection in MRC-5 cells, innate
immunity is not completely inhibited in these cells as indicated by the remaining >20-fold overexpression
of the PRRs TLR3 and RARRES3 and >5-fold overexpression of IFNB1, STAT1, and EIF2AK2. In fact,
IFNB 1 knockdown appears to have little or no effect on the inhibition of proliferation observed in ivT-
RNA-transfected cells (Fig. 5.5), suggesting that in cells transfected with both ivT RNA and IFNB 1
siRNA, either the remaining low level of IFNB 1 expression is sufficient to prevent the cells from
proliferating or the cells are prevented from proliferating by a mechanism independent of interferon-0
signaling.
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Figure 5.4. Gene expression after interferon-P knockdown. A: MRC-5 fibroblasts were pre-
transfected with IFNB 1 siRNA, and then co-transfected with ivT RNA and siRNA two days later. Gene
expression was measured 24 hours after the second transfection. B: MRC-5 fibroblasts were co-
transfected with ivT RNA and IFNB1 siRNA, and the expression of TLR3, RARRES3, and IFNB1 was
measured after 24 hours. Error bars show the pooled standard deviation of replicate samples.
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Figure 5.5. Cell proliferation after interferon-p knockdown. MRC-5 fibroblasts were transfected
with the indicated siRNA on day 0, and then co-transfected with 2.5/tg ivT RNA and siRNA on day 3.
A,B: The expression of IFNB 1 and TP53 was measured 24 hours after the second transfection. GAPDH
was used as a loading control. Error bars show the pooled standard deviation of replicate samples. C:
The confluency of each dish of cells was estimated at the indicated times. As in the experiment described
in Figure 5.1, the cells that received no ivT RNA (diamonds) recovered quickly after the second
electroporation, while the cells that received ivT RNA (squares) exhibited proliferation delayed by
approximately 48 hours. Also as before, TP53 knockdown (triangles, circles) shortened the recovery time
by about half. However, IFNB 1 knockdown (crosses, circles) had little or no effect on proliferation.
Data points are connected for clarity.
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5.3. Inhibiting the innate-immune response by knocking down toll-like receptor 3 (TLR3), toll-like
receptor adaptor molecules 1 and 2 (TICAM1 and TICAM2), virus-induced signaling adapter
(VISA), TANK-binding kinase 1 (TBK1), interferon regulatory factor 3 (IRF3), signal transducer
and activator of transcription 1 and 2 (STAT1 and STAT2), eukaryotic translation initiation factor
2-alpha kinase 2 (EIF2AK2), tumor protein p53 (TP53), and cyclin-dependent kinase inhibitor 1A
(CDKN1A)
Although the innate-immune response is initiated and regulated by intra- and extracellular signaling
pathways containing a great deal of redundancy, many viruses have evolved mechanisms to disrupt
innate-immune signaling, enabling persistent infection (for a recent review of innate-immune disruption
by Hepatitis C, a ssRNA virus, see Bode, 2007). To test whether RNAi knockdown of one or more of the
factors involved in innate-immune signal transduction would inhibit the innate-immune response elicited
by ivT-RNA transfection, various combinations of siRNAs targeting TLR3, TICAM 1, TICAM2, VISA,
TBK1, IRF3, STAT1, STAT2, EIF2AK2, TP53, and CDKN1A were delivered to cells by electroporation
48 hours before a second electroporation with ivT RNA and additional siRNA. The levels of expression
of IFNB 1 and the genes targeted for knockdown were measured 24 hours after the second electroporation
by quantitative RT-PCR (Figs. 5.6 A-C, 5.7 A, B). Transfections were split into two independent
experiments to minimize sample-handling time. Transfected cells were monitored for several days, and
estimates of confluency were made each day to determine if knocking down the selected genes had an
effect on cell proliferation (Figs. 5.6 D and 5.7 C).
Although knocking down any of the selected genes resulted in a significant reduction of IFNB 1
overexpression, only knockdown of STAT2 or EIF2AK2 had an observed effect on cell proliferation.
The effect of knocking down either STAT2 or EIF2AK2 was characterized by a shortened recovery time
after ivT-RNA transfection. In both cases, cells co-transfected with siRNA and ivT RNA appeared to
reach the same level of confluency as mock-transfected cells after approximately 36 hours, as opposed to
the 48 hours required for the no-siRNA control. As opposed to TP53-knockdown, which resulted in an
increased confluency in knockdown cells compared to the no-siRNA control only 24 hours after
transfection (Fig. 5.1), the increased confluency of STAT2 and EIF2AK2 knockdown cells compared to
the no-siRNA control was first observed 48 hours after transfection, suggesting that while STAT2 or
EIF2AK2 knockdown alone may be insufficient to inhibit the innate-immune response elicited by ivT-
RNA transfection, knocking down these genes may contribute to an increased rate of recovery after the
ivT RNA has been degraded by the cell.
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Figure 5.6. Knockdown of genes involved in the innate-immune response (1). MRC-5 fibroblasts
were pre-transfected with the indicated siRNAs (200nM by electroporation), and then co-transfected with
both siRNA and 2.5pg ivT RNA 48 hours later. Gene expression was measured 24 hours after the second
transfection, and is shown relative to mock-transfected cells. A: Gene expression of TLR3, STAT2,
VISA, TBK1, and IRF3 was measured after knocking down each gene. B: Gene expression of TLR3,
TICAM1, and TICAM2 was measured after combined knockdown of all three genes. C: IFNB 1
expression of cells transfected with the indicated siRNAs. D: The confluency of transfected cells was
estimated at the indicated times. Proliferation of cells transfected with siRNAs targeting genes other than
STAT2 was indistinguishable from the no-siRNA control. Error bars in A-C show the pooled standard
deviation of replicate samples. Data points in D are connected for clarity.
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Figure 5.7. Knockdown of genes involved in the innate-immune response (2). A,B: MRC-5
fibroblasts were transfected and gene expression was measured as in the previous figure. C: The
confluency of transfected cells was estimated at the indicated times. Proliferation of cells transfected with
siRNAs targeting genes other than EIF2AK2 was indistinguishable from the no-siRNA control.
Differences in post-transfection confluency (day 0 and day 2+) between this and the previous experiment
are the result of different plating densities after electroporation. Error bars in A-B show the pooled
standard deviation of replicate samples. Data points in C are connected for clarity.
5.4. Evading the innate-immune response with N6-methyladenosine-substituted ivT RNA
Aside from the m7G cap, N6-methyladenosine (m6A) is the most abundant modified base in eukaryotic
mRNA, and is found at a frequency of 1-10 nucleotides per average-length transcript62' 63. m6A inhibits
A-U base pairing, and may destabilize the secondary structure of mRNA in cells. ivT RNA containing
increasing amounts of m6A has been shown to evade detection by TLR3 and TLR7, while unsubstituted
ivT RNA elicits an innate-immune response in cells expressing either of these receptors 61, suggesting that
m6A substitution may have evolved in eukaryotes as a marker of endogenous RNA, allowing the cell to
specifically detect and respond to RNA of bacterial or viral origin.
Transcripts were synthesized as described in Section 3.2, but substituting m6ATP for 0, 2%, 10%,
50%, or 100% of the ATP in the ivT reaction (Fig 5.8). Because T7 RNA polymerase has been shown to
incorporate m6A in vitro at the same frequency as the unmodified nucleotide under standard reaction
conditions61, the final fraction of modified bases in the synthetic transcripts was assumed to correspond
roughly to the fraction of modified nucleotide in the ivT reaction. However, the yield of ivT reactions
was observed to decrease with increasing amounts of m6ATP (Fig. 5.8 A), with the reaction containing
no unmodified nucleotide yielding approximately 40% the amount of RNA as the reaction containing no
modified nucleotide, indicating that under these reaction conditions, the T7 polymerase may more readily
incorporate the unmodified nucleotide. As a result, the reactions containing a mixture of modified and
unmodified nucleotides may have yielded transcripts with a modified-to-unmodified base ratio
significantly lower than the fraction of modified nucleotide in the ivT reaction.
Cells were transfected with ivT RNA with various levels of m6A substitution, and the amount of
translated protein was measured by western blot 12 hours after transfection (Fig. 5.9). The amount of
protein translated from the ivT RNA decreased with increasing amount of m6A substitution, with 10%-
substituted RNA yielding approximately half as much protein as unsubstituted RNA, and 50% and 100%-
substituted RNA yielding less than 10% as much protein as unsubstituted RNA. These data strongly
suggest that ivT RNA with large amounts of m6A substitution is much less efficiently translated by
MRC-5 cells than unsubstituted RNA.
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Figure 5.8. Synthesis of m6A-substituted ivT RNA. 20AL in vitro-transcription reactions (Table B.9)
were carried out at 10C for 20 hours using Template A and substituting m6ATP (TriLink) for 0%, 2%,
10%, 50%, or 100% of the ATP in the reaction. After in vitro transcription, the RNA was purified
(RNeasy mini kit, Qiagen), and quantified (Quant-iT system, Invitrogen). The synthesis was repeated
several times. A: The yield of a representative experiment. The increase in yield obtained by adding
small amounts of m6ATP (2%, 10%) was observed consistently in independent experiments. B: RNA
synthesized in ivT reactions containing different amounts of m6ATP was capped and polyadenylated
(Tables B. 10, B. 11). 1 g of RNA from each reaction both before and after capping and poly(A)-tailing
was analyzed by denaturing formaldehyde-agarose gel electrophoresis. The RNA from each reaction
traveled as a sharp band of the expected size before capping and tailing, and the tailing reaction added a
poly(A) tail of approximately 150nt.
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Figure 5.9. Protein translation from m6A-substituted ivT RNA. A: 1.5Azg of capped, poly(A)-tailed
ivT RNA with various levels of m6A substitution was delivered to MRC-5 fibroblasts by electroporation.
Twelve hours later a western blot was performed to measure the amount of translated protein. Beta actin
was used as a loading control. H9 hES cells, which endogenously express the protein encoded by
Transcript A, was used for comparison. B: The intensity of each band was averaged across the width of
the lane, and the peak lane-averaged intensity was normalized to ACTB. The normalized, peak lane-
averaged intensity is plotted relative to that of the H9 band. As is evident from the plot, RNA with a large
amount of m6A substitution is translated less efficiently by MRC-5 fibroblasts than unsubstituted RNA.
To assess the degree to which ivT RNA with different levels of m6A substitution elicits an
innate-immune response when delivered to cells, total RNA was extracted from the cells transfected with
m6A-substituted ivT RNA 24 hours after transfection, and the expression of IFNB 1 was measured by
quantitative RT-PCR (Fig. 5.10 A). Both the 2%- and 10%-substituted RNA elicited a level of IFNB 1
overexpression comparable to that elicited by unsubstituted RNA (approximately 5000-fold), while the
level of IFNB 1 overexpression in samples transfected with 50% and 100%-substituted RNA was
significantly lower, although IFNB 1 was still >400-fold overexpressed in these samples relative to mock-
transfected cells. These data suggest that while ivT RNA with a large amount of m6A substitution can
partially evade detection by the innate immune system, even completely substituted RNA (excluding the
poly(A) tail) is capable of eliciting an innate-immune response when delivered to cells by electroporation.
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Figure 5.10. IFNB1 expression and proliferation after transfection with m6A-substituted ivT RNA.
A: IFNB 1 expression was measured in cells transfected with ivT RNA with various levels of m6A
substitution 24 hours after electroporation. Although the 50%- and 100%-substituted RNA elicited
approximately 10-fold less IFNB 1 expression than the less-substituted RNA, IFNB 1 was overexpressed
by >400 fold in all samples transfected with ivT RNA compared to mock-transfected cells. GAPDH was
used as a loading control. B: MRC-5 fibroblasts were transfected with 1.5lig of ivT RNA (HUSK
Transcript A) with various levels of m6A substitution, and estimates of confluency were made at the
indicated times. All of the cultures that received ivT RNA (squares) proliferated at approximately the
same rate, regardless of the level of m6A substitution. Data points are connected for clarity.
The cells transfected with m6A-substituted ivT RNA were monitored for several days and
estimates of confluency were recorded each day (Fig. 5.10 B). All of the cultures transfected with ivT
RNA exhibited growth delayed by approximately 48 hours, regardless of the level of m6A substitution.
Because the amount of protein translated from the 100%-m6A-substituted transcript was barely detectable
(Fig. 5.9), the observation that transfection with this transcript results in the same degree of proliferation
inhibition as transfection with the unsubstituted transcript strongly suggests that the cytostatic effect of
ivT-RNA transfection is mediated by the ivT RNA itself, and not the protein that it encodes.
5.5. Extended transient transfection by repeated delivery of in vitro-transcribed RNA
Three methods were identified that each mitigate to some degree the innate-immune response elicited by
ivT-RNA transfection as measured both by reduced IFNB 1 expression and by shortened post-transfection
recovery time: 1. TP53 knockdown, 2. Innate-immune-response-amplification disruption by IFNB1
knockdown, and 3. Innate-immune-response inhibition by knockdown of additional genes involved in
innate-immune signal transduction. These three methods were combined to determine whether cells
could be repeatedly transfected with ivT RNA, with a transfection frequency on the order of the
intracellular lifetime of the encoded protein, to achieve a high level of expression sustained through
multiple rounds of cell division.
MRC-5 fibroblasts were transfected with siRNA Mix 1 (400nM TP53, 200nM STAT2, and
200nM EIF2AK2) or siRNA Mix 2 (400nM TP53, 200nM STAT2, 200nM EIF2AK2, 200nM IFNB1,
200nM TLR3, and 200nM CDKN1A), and then repeatedly transfected with ivT RNA over the course of
several days. The expression of genes that were previously found to be >5-fold overexpressed in ivT-
RNA-transfected cells (TLR3, RARRES3, IFNB1, STAT1, STAT2, and EIF2AK2), as well as the
expression of TP53 and CDKN1A were measured 24 hours after the first transfection with ivT RNA to
determine both the knockdown efficiency of each siRNA under these conditions, and the effectiveness of
each siRNA mixture in inhibiting the innate-immune response elicited by ivT-RNA transfection (Fig.
5.11). In cells transfected with siRNA Mix 1, expression of all of the genes measured was reduced
compared to mock-transfected cells, with several genes (TLR3, IFNB 1, STAT2, and EIF2AK2) showing
>90% knockdown. In cells transfected with siRNA Mix 2, expression of many of the genes measured
was reduced further, and in these cells only RARRES3 and STAT1 (the two genes not targeted with
siRNA) were >5-fold overexpressed compared to mock-transfected cells, although both were significantly
less overexpressed than in cells that received no siRNA.
As shown in Figure 4.4, transfection with HUSK Transcript B results in significant protein
expression for approximately 18-24 hours, while transfection with HUSK Transcript F results in
significant protein expression for more than 48 hours. Further analysis of the time-evolution of
expression after transfection with HUSK Transcript F revealed that the protein encoded by this transcript
reaches approximately 50% of its peak level 3 days after transfection. However, because transfection
with ivT RNA results in decreased proliferation, the duration of protein expression measured in these
experiments may be significantly longer than it would have been had the cells been actively proliferating.
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Figure 5.11. Gene expression after combined knockdown of innate-immune-related genes. MRC-5
fibroblasts were transfected with siRNA Mix 1 (400LM TP53, 200nM STAT2, and 200nM EIF2AK2) or
siRNA Mix 2 (400nM TP53, 200nM STAT2, 200nM EIF2AK2, 200nM IFNB1,200nM TLR3, and
200nM CDKNlA) on day 0, and then transfected with 0.5ttg HUSK Transcript B or F and additional
siRNA after 48. Gene expression was measured 24 hours after the second transfection. GAPDH was
used as a loading control. Error bars show the pooled standard deviation of replicate samples.
To achieve a sustained high level of protein, cells were transfected either with HUSK Transcript
B, three times at 24-hour intervals, or with HUSK Transcript F, two times at a 48-hour interval. The
confluency of each dish of transfected cells was monitored to determine the effect of co-transfoction with
ivT RNA and siRNA Mix 1 or 2 on cell proliferation (Fig. 5.12). While cells appeared to recover from
the first transfection with ivT RNA, many of the cells that did not receive siRNA died after the second
ivT-RNA transfection, likely due to hypersensitization to exogenous RNA as indicated by >100-fold
overexpression of TLR3 and >50-fold overexpression of RARRFS3 compared to mock-transfected cells.
However, cells that received either siRNA Mix 1 or 2 exhibited high viability after every transfection, and
the confluency of these cultures remained within 10% of that of the mock-transfected cells throughout the
experiment. Interestingly, the cells that were transfected with ivT RNA and siRNA three times at 24-hour
intervals recovered quickly enough that the confluency of these cultures decreased only by approximately
38
10% each day. Because of sample loss due to handling (trypsinizing, transferring into and out of the
electroporation cuvette, etc.) and because after each transfection approximately 10-15% of the cells were
reserved for protein and RNA analysis, the observed rate of recovery is likely high enough to allow an
unlimited number of transfections at 24-hour intervals.
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Figure 5.12. Cell proliferation after repeated transfection with ivT RNA. A: MRC-5 fibroblasts
were transfected with siRNA Mix 1 (400nM TP53, 200nM STAT2, and 200nM EIF2AK2) or siRNA Mix
2 (400nM TP53, 200nM STAT2, 200nM EIF2AK2, 200nM IFNB1, 200nM TLR3, and 200nM
CDKN1A) on day 0, and then transfected with 0.51g HUSK Transcript B on days 2, 3, and 4. Additional
siRNA was included on days 2 and 4. After each transfection, approximately 10-15% of the cells were
reserved for protein and RNA analysis, and the rest were plated in 10cm dishes. The confluency of each
dish was estimated at the indicated times. B: Cells were transfected as in A, but with 0.5#tg HUSK
Transcript F, and no transfection was performed on day 3. Data points are connected for clarity.
Whole-cell lysates were prepared every 12 hours after the first transfection with ivT RNA (day 2),
and the level of protein encoded by the ivT RNA was assessed by western blot (Fig. 5.13). While the
level of protein encoded by Transcript F reaches approximately 50% of its peak level 3 days after a single
transfection (not shown), the cells transfected twice with Transcript F maintained a high level of protein
expression through the third day after the first transfection, which increased slightly after the second
transfection, and then fell to approximately 50% of its peak level on day 7, 5 days after the first
transfection, 3 days after the second (and last) transfection. This protein-expression profile, together with
the fact that the transfected cells are proliferating rapidly (Fig. 5.12 B), suggests that an approximately
steady-state level of the protein encoded by Transcript F can be maintained through many cell divisions
by repeated transfection at 48-hour intervals.
The protein encoded by Transcript B however, although highly expressed 12 hours after each
transfection, was barely detectable 24 hours after each transfection, suggesting that most of the protein
produced as a result of each transfection was degraded by the time the following transfection was
performed. However, although the cells were clearly proliferating, because the cells were not
synchronized, the start of mitosis relative to each transfection is not known, and as a result the precise
level of transduced protein expression during DNA replication is not clear from these data. Additional
experiments are required to determine whether the observed protein-expression profile is sufficient to
promote gene activation, or whether a modified protocol (more-frequent transfections, transfection with a
larger quantity of ivT RNA, etc.) is required. Also, the level of protein expression 12 hours after
transfection with Transcript B seems to decrease with each subsequent transfection. One possible
explanation could be that ivT-RNA degradation products are used as substrates by the cell's RNAi
machinery, which is then able to degrade a larger amount of ivT RNA after each subsequent transfection.
Additional experiments are required to determine whether this or another mechanism is responsible for
the observed decrease in peak protein level after subsequent transfections.
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Figure 5.13. Protein expression after repeated transfection with ivT RNA. MRC-5 fibroblasts were
transfected as described in the previous figure. Whole-cell lysates were prepared at the indicated times
and analyzed by western blot using antibodies against the proteins encoded by Transcripts B and F. Note
that cells were transfected with only siRNA on day 0 and that the first transfection with ivT RNA
occurred on day 2. ACTB was used as a loading control.
6. CONCLUSION
The future of medicine will be characterized by therapies based on techniques for controlling cell type.
Replacing cells, tissues, and organs lost to disease or injury requires methods of generating new tissue-
specific cells in vitro for implantation into damaged areas of the body. Transfecting cells with DNA,
RNA or proteins provides a means not only for generating these tissue-specific cells by directing the
differentiation of stem cells in vitro, but also for unraveling the molecular pathways that control cell-type
specification and maintenance by selectively transducing the overexpression of the genes involved in
these processes. While transforming cells by DNA transfection represents a simple method of
transducing stable gene expression, the safety issues that arise from altering cell type by genetic
modification will likely limit the use of this technique in regenerative-medicine applications. Controlling
cell type by transient transfection with protein or RNA offers an appealing alternative as these molecules,
once they have performed their function, are metabolized by the cell, leaving it genetically
indistinguishable from the donor. Transfection with RNA in particular offers two critical advantages: 1.
RNA can be easily synthesized in vitro for any protein of reasonable length and a known sequence, and 2.
Many copies of a protein can be synthesized by the cell from each RNA molecule, minimizing the amount
of material that must be delivered, thus minimizing cellular stress.
We have demonstrated a method of transducing quasi-stable protein expression by frequent,
repeated transfection of cultured cells with ivT RNA. By suppressing the innate-immune response of
MRC-5 human fibroblasts to exogenous RNA by combined knockdown using siRNAs targeting TP53,
STAT2, EIF2AK2, IFNB 1, TLR3, and CDKN1A, and by using an electroporation protocol designed to
minimize cellular stress, repeated transfections at 24-hour intervals were performed with no observed
decrease in the rate of proliferation compared to mock-transfected cells. This is in stark contrast to cells
transfected with ivT RNA, but without siRNA. Although these cells appeared to recover quickly from the
first transfection, viability sharply decreased after the second transfection, likely due to hypersensitization
of the cells to exogenous RNA as indicated by a measured >100-fold overexpression of TLR3 and >50-
fold overexpression of RARRES3 compared to mock-transfected cells.
For a protein with a half-life of 3 days, two transfections using this technique extended the
effective protein half-life to 5 days, with a stable, high level of protein expression observed for the first 3
days after transfection. Repeated transfection with a less stable protein (intracellular lifetime of 18-24
hours) at intervals of 24 hours generated a high level of protein expression 12 hours after each
transfection, which decreased before the next transfection, suggesting that more frequent transfections,
modification to the ivT RNA to increase its stability or other modifications to the transfection protocol
may be required to achieve a stable level of expression of proteins with short intracellular lifetimes.
However, because a high level of protein expression may only be required for a short time during each
cell cycle to modify the epigenetic state of a target gene, the quasi-stable protein expression demonstrated
here may be sufficient to achieve gene activation. Measurements of the expression of genes known to
contain binding sites for proteins encoded by the transfected ivT RNA would provide valuable
information regarding the protein-expression requirements for gene activation and cell-type conversion.
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APPENDIX A: METHODS
Mouse embryonic fibroblast (MEF) derivation. Mouse embryonic fibroblasts were derived from E13
CF-1 mice (Charles River Laboratories). Animals were administered 250mg/kg Avertin (2,2,2-
tribromoethanol) by interperitoneal injection, and euthanized by cervical dislocation. Uterine horns from
each animal were removed from the peritoneum, placed in a 10cm Petri dish and rinsed with PBS.
Embryonic sacs were cut, and embryos removed, rinsed with PBS, and counted. Visceral tissue was
separated and discarded, and embryos were rinsed again with PBS. Remaining tissue was minced with
dissecting scissors, 2mL trypsin was added, and tissue was further minced until no large pieces remained.
An additional 5mL trypsin was added, and dishes were placed in a 37C, 5% CO 2 incubator for 20-30
minutes. MEF Media (see Appendix C) supplemented with penicillin and streptomycin was added, and
cells were cultured in T75 flasks (approximately 3 embryos per flask). The following day, cells from a
total of 6 mice were pooled into two groups, MEF land MEF2, and were frozen in MEF Media
supplemented with 10% DMSO and stored in liquid nitrogen. A sample from each group was tested for
mycoplasmal contamination (Bionique, test M-250). Both samples tested negative for mycoplasmal
contamination by both DNA fluorochrome staining and live-culture methods.
Human embryonic stem (hES) cell culture. H9 human embryonic stem cells were obtained from the
National Stem Cell Bank at passage 24, and were cultured on irradiated MEFs as described'. Cells from
frozen stocks (in hES-Cell Media + 10% DMSO + 30% Defined FBS) were seeded on plates coated with
BME (Trevigen), and cultured in MEF 1-Conditioned Media (see Appendix C). hES cells formed large
colonies consisting of small, rapidly-dividing, Oct4- and Nanog-positive cells, often with larger
cobblestone-like, Oct4- and Nanog-negative cells at the periphery when cultured without the ROCK
inhibitor Y-27632. Undifferentiated colonies were maintained by manually removing these differentiated
cells with a pulled glass pipette. The cells exhibited a normal karyotype at passage 24.
Fibroblast culture. Primary human fibroblasts from normal fetal lung tissue (MRC-5) were obtained
from the ATCC and were cultured according to their recommendations.
In vitro-transcription template synthesis. Total RNA was extracted from H9 hES cells and enriched
for poly(A)+ mRNA (Oligotex, Qiagen). Transcripts of interest and P-globin were reverse transcribed
using an RNase H- reverse transcriptase (MonsterScript, Epicentre). Template components were
amplified using a high-fidelity polymerase (Phusion Hot Start, NEB) and ligated with E. coli DNA ligase
(NEB). Ligation products were amplified and gel purified (Gel Extraction Kit, Qiagen) in preparation for
in vitro transcription.
In vitro transcription. Capped, poly(A)+ ivT RNA was synthesized using the mScript mRNA
Production System (Epicentre). The temperature and duration of the in vitro-transcription reaction were
optimized for specificity and yield.
Denaturing formaldehyde-agarose gel electrophoresis. Transcripts were analyzed both before and
after poly(A) tailing by denaturing formaldehyde-agarose gel electrophoresis to ensure that they were the
expected size and to measure the length of the poly(A) tail. Three volumes of Formaldehyde Load Dye
(Ambion) were added to each sample, and the samples were denatured at 70C for 15min, then loaded into
the wells of a 1.5% formaldehyde-agarose gel (NorthernMax, Ambion). An RNA ladder (Millennium
Markers, Ambion) was used for size comparison.
Lipid-mediated transfection. ivT RNA was delivered to MRC-5 fibroblasts by lipid-mediated
transfection (TransIT, Mirus) following the manufacturer's instructions.
Electroporation. Cells were trypsinized, washed once in Opti-MEM (Invitrogen), and resuspended in a
total volume of 50pL Opti-MEM in a standard electroporation cuvette with a 2mm gap. A 150uF
capacitor charged to between 110V and 145V was discharged into the cuvette to electroporate the cells.
Warm media was added, and the cells were plated in 10cm dishes or multi-well plates.
Quantitative RT-PCR. Primers and molecular-beacon probes were designed to detect HUSK
Transcripts A-F. Amplicons were designed to span the stop codon to prevent the coamplification of
endogenous transcripts. Standard curves were generated to assess the efficiency of each reaction.
TaqMan Gene Expression Assays (Applied Biosystems, Table A. 1) were used to measure levels of
endogenous mRNA. RNA was extracted from cells and purified (RNeasy mini kit, Qiagen) before RT-
PCR (iScript One-Step RT-PCR Kit, Bio-Rad). The RT-PCR protocol consisted of a 50C, 10 min reverse
transcription step, followed by an initial denaturation step of 95C for 5min, and 45 cycles of 95C for
15sec and 55C for 30sec.
siRNA-mediated knockdown. Cells were electroporated (see protocol above) in Opti-MEM containing
siRNA (Applied Biosystems, Table A. 1) at various concentrations.
Table A.1. TaqMan Gene Expression Assays and siRNAs.
Gene TaqMan Assay siRNA
1 TP53 Hs00153340 ml s605
2 TLR3 Hs00152933_ml s235
3 TLR7 Hs00152971 ml
4 RARRES3 Hs00184937_ml
5 IFNB1 Hs02621180 sl s7187
6 TICAM1 Hs00706140_sl s45113
7 TICAM2 Hs01934488 sl s51478
8 VISA Hs00325038_ml s33178
9 STAT1 Hs00234829_ml s277
10 STAT2 Hs00237139_ml s13530
11 EIF2AK2 Hs00169345_ml s11185
12 IRF3 Hs00155574 ml s7509
13 TBK1 Hs00179410_ml s762
CDKN1A Hs00355782_ml s415
Immunocytochemistry. Cells were rinsed in PBS and fixed for 10 minutes in 4% paraformaldehyde.
Cells were then permeabilized in 0.1% Triton X-100 and blocked for 30 minutes in 2% skim milk. After
blocking, cells were incubated with primary antibodies overnight at 4C, washed three times in 0.05%
Tween 20, and incubated with FITC- and CY3-conjugated secondary antibodies for 1 hour at room
temperature. Cells were washed three times in 0.05% Tween 20, incubated with Hoechst 33342 for one
minute, rinsed, mounted in 50% glycerol in PBS, and imaged by fluorescence microscopy.
Polyacrylamide gel electrophoresis (PAGE) and western blot. Whole-cell lysates (Qproteome
Mammalian Protein Prep Kit, Qiagen) were separated on a 12% polyacrylamide gel (ProSieve 50, Lonza)
under reducing, denaturing conditions. Proteins were transferred onto a PVDF membrane (Immobilon-FL,
Millipore) in CAPS buffer, pH 11. The membrane was blocked in 3% BSA in TBST and probed with
appropriate antibodies. Quantum-dot-conjugated secondary antibodies (Invitrogen) were used for
multiplexed probing. [-actin (Abcam 8226) was used as a loading control.
APPENDIX B: IVT-RNA SYNTHESIS
Table B.1. Reverse transcription.
Final concentration Volume/LL Reaction conditions
mRNA Template 500ng 7.8 1: 65C-1min
2pM ivT Reverse Primer 0.25pM 2.5 2: 60C-45min
1:10 10mM dNTP Mix (Promega) 2001pM 4 3: 90C-5min
MonsterScript Reverse Transcriptase 1:20 1
5X MonsterScript Buffer 1X 4
H20 0.7
4: 4C-hold
Total
Component
5X Phusion HF Buffer
Final concentration I Volume/aL Reaction conditions
1: 98C-lmin I
10mM dNTP Mix 20011M 0.5 2: 98C-15sec
51.M CDS Forward Primer .5pM 2.5 3: 72C-4min
5SIM CDS Reverse Primer .51iM 2.5 4: 72C-10min
Gene-Specific RT Reaction 25ng 1 5: 4C-hold
Phusion Hot-Start DNA Polymerase 0.5U 0.25
x35 cycles
DMSO 5% 1.25
H20 12
25 Total
Table B.3. HBB 5'-UTR amplification.
Component
5X Phusion HF Buffer
Final concentration
1X
Volume/AL Reaction conditions
1: 98C-1min
10mM dNTP Mix 2001tM 0.5 2: 98C-15sec
5lM HBB 5-UTR Forward Primer .5ltM 2.5 3: 70C-20sec
51M HBB 5-UTR Reverse Primer .5kM 2.5 4: 70C-2min
Phusion Hot-Start DNA Polymerase 0.5U 0.25 5: 4C-hold
DMSO 5% 1.25
x45 cycles
Total
Component
Table B.2. CDS amplification.
H20 13
Table B.4. HBB 3'-UTR amplification.
Cnmnnnnt
5X Phusion HF Buffer
Final concentration I Volume/uL
nr' 'Fi nal ..... ... . I Reaction conditions
1: 98C-1min
10mM dNTP Mix 200l1M 0.5 2: 98C-15sec
5pM HBB 3-UTR Forward Primer .511M 2.5 3: 68C-20sec
51pM HBB 3-UTR Reverse Primer .5p.M 2.5 4: 68C-2min
HBB RT Reaction 25ng 1 5: 4C-hold
Phusion Hot-Start DNA Polymerase 0.5U 0.25
DMSO 5% 1.25
H20 12
x45 cycles
25 1 Total
Table B.5. ivT-template-component digestion.
Final concentration Volume/L Reaction conditions
10X NEBuffer 1 1X 5 1: 37C-1hr
10OX BSA 1X 0.5 2: 65C-20min
CDS or HBB UTR PCR Product 0.25-1.5p.g 30
Nhel 2.5U 0.25
Agel 2.5U 0.5
H20 13.75
50 Total
Table B.6. ivT-template-component ligation.
Component Final concentration Volume/iL Reaction conditions
10X E.coli DNA Ligase Buffer 1X 5 1: 16C-18hr
Digested CDS PCR Product 10-50nM 30 2: 65C-20min
Digested HBB 5-UTR PCR Product 50nM
50 1 Total
Comoonent
Digested HBB 3-UTR PCR Product 25nM 5
E.coli DNA Ligase 5U 0.5
H20 4.5
Table B.7. Ligation-product amplification.
Component
5X Phusion HF Buffer
Final concentration Volume/uLVolurne/ Reaction conditionn
10mM dNTP Mix 200jpM 0.5 2: 98C-15sec
5plM HBB 5-UTR Forward Primer .5lpM 2.5 3: 68C-5min
5pM HBB 3-UTR Reverse Primer .5pM 2.5 4: 68C-10min
HBB-UTR-Stabilized Template .5ng 2.5 5: 4C-hold
Phusion Hot-Start DNA Polymerase 0.5U 0.25
DMSO 5% 1.25
H20 10.5
Total
Table B.8. Large-scale amplification.
Component
5X Phusion HF Buffer
Final concentration Volume/uL.
I + I
1: 98C-1min
10mM dNTP Mix 200lpM 0.5 2: 98C-15sec
5pM HBB 5-UTR Forward Primer .5pM 2.5 3: 68C-5min
5pM HBB 3-UTR Reverse Primer .5pM 2.5 4: 68C-10min
HBB-UTR-Stabilized Template lOng 0.5 5: 4C-hold
Phusion Hot-Start DNA Polymerase 0.5U 0.25
DMSO 5% 1.25
H20 12.5
25 Tc
Table B.9. In vitro transcription.
Component Volume/ulL Reaction conditions
RNase-Free Water 0.8 1: 10OC-20hr
mScript 10X Transcription Buffer 2
NTP Solution 7.2
100mM DTT 2
mScript T7 Enzyme Mix 2
T7 Template 6
20 Total
otal
x35 cycles
Reaction conditions
x30 cycles
Reaction conditions
1: 98C-1min
Table B.10. m7G capping.
ComDonent Volume/uL Reaction conditions
10X ScriptCap Capping Buffer 10 1: 37C-1hr
20mM GTP 5
20mM SAM 1
SUPERaseln 5
mScript Capping Enzyme 4
mScript 2'-O-Methyltransferase 4
Heat-Denatured RNA 71
100 Total
Table B.11. Poly(A) tailing.
Component Volume/pL Reaction conditions
mScript 10X Tailing Buffer 12 1: 37C-40min
SUPERaseln 1
124 1 Total
20mM ATP 6
mScript Poly(A) Polymerase 5
5'-Capped ivT RNA 100
APPENDIX C: MEDIA FORMULATIONS
MEF Media
Component Final concentration
DMEM
Fetal bovine serum (FBS), heat-inactivated at 56C for 30min 10%
Non-essential amino acids 100X solution 1X
hES-Cell Media'
Component Final concentration
DMEM/F12
Knockout Serum Replacer 20%
L-glutamine ImM
P-mercaptoethanol 7gL/L
Non-essential amino acids 100X solution 1X
bFGF 4ng/mL
MEF-Conditioned Media
Component Final concentration
hES-Cell Media -bFGF conditioned for 24 hours on irradiated MEF 1 (8000rad)
bFGF 4ng/mL
Y-27632 10jM
MRC-5 Fibroblast Media
Component Final concentration
MEM
Fetal bovine serum (FBS) 10%
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